リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Sarcomatoid mesothelioma diagnosed in a patient with mesothelioma in situ: a case report on morphologic differences after 9-month interval with details analysis of cytology in early-stage mesothelioma」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Sarcomatoid mesothelioma diagnosed in a patient with mesothelioma in situ: a case report on morphologic differences after 9-month interval with details analysis of cytology in early-stage mesothelioma

Yoshida, Miho Jimbo, Naoe Tsukamoto, Ryuko Itoh, Tomoo Kawahara, Kunimitsu Mitsui, Suguru Tanaka, Yugo Maniwa, Yoshimasa 神戸大学

2023.11.28

概要

Background: Overlapping morphological features of mesothelial cells have been rendered it difficult to distinguish between reactive and malignant conditions. The development of methods based on detecting genomic abnormalities using immunohistochemistry and fluorescence in situ hybridization have contributed markedly to solving this problem. It is important to identify bland mesothelioma cells on cytological screening, perform efficient genomic-based testing, and diagnose mesothelioma, because the first clinical manifestation of pleural mesothelioma is pleural effusion, which is the first sample available for pathological diagnosis. However, certain diagnostic aspects remain challenging even for experts. Case presentation: This report describes a case of a 72-year-old man with a history of asbestos exposure who presented with pleural effusion as the first symptom and was eventually diagnosed as mesothelioma. Mesothelioma was suspected owing to prominent cell-in-cell engulfment in mesothelial cells on the first cytological sample, and the diagnosis of mesothelioma in situ was confirmed by histology. Unexpectedly, sarcomatoid morphology of mesothelioma was found in the second pathology samples 9 months after the first pathological examination. Both the mesothelioma in situ and invasive lesion showed immunohistochemical loss of methylthioadenosine phosphorylase (MTAP) and homozygous deletion of cyclin dependent kinase inhibitor 2A (CDKN2A) on fluorescence in situ hybridization. The patient received medication therapy but died of disease progression 12 months after the diagnosis of the sarcomatoid morphology of mesothelioma. Conclusion: Our case suggests that cell-in-cell engulfment can be conspicuous in early-stage mesothelioma with inconspicuous nuclear atypia and few multinucleated cells. In addition, the presence of MTAP loss and CDKN2A homozygous deletion are suspected to be involved in early formation to invasive lesions and/or sarcomatoid morphology. We believe that it is important to consider genetic abnormalities when deciding on individual patient management. Furthermore, cases of mesothelioma, even those of an in situ lesion, with MTAP loss and/or CDKN2A deletion should be carefully followed up or subjected to early treatment.

この論文で使われている画像

参考文献

1. Eccher A, Girolami I, Lucenteforte E, Troncone G, Scarpa A, Pantanowitz

L. Diagnostic mesothelioma biomarkers in effusion cytology. Cancer

Cytopathol. 2021;129:506–16. https://​doi.​org/​10.​1002/​cncy.​22398.

2. Hamakawa S, Mori K, Kashiwazaki Y, Tanabe M, Kondo Y, Sakamaki K, et al.

Molded mesothelial cells with hump-like cytoplasmic process in effusion

cytology of malignant mesothelioma. J Jpn Soc Clin Cytol. 2003;42:10–6.

https://​doi.​org/​10.​5795/​jjscc.​42.​10.

3. Haefliger S, Savice Prince S, Rebetez J, Borer H, Bubendorf L. Putative

malignant pleural mesothelioma in situ (MPMIS) with sequential acquisition of genomic alterations on fluorescence in situ hybridization (FISH)

examination. Acta Cytol. 2021;65:99–104. https://​doi.​org/​10.​1159/​00050​

9886.

4. Minami K, Jimbo N, Tanaka Y, Hokka D, Miyamoto Y, Itoh T, et al. Malignant

mesothelioma in situ diagnosed by methylthioadenosine phosphorylase

loss and homozygous deletion of CDKN2A: a case report. Virchows Arch.

2020;476:469–73. https://​doi.​org/​10.​1007/​s00428-​019-​02674-x.

5. Nishikubo M, Jimbo N, Tanaka Y, Tachihara M, Itoh T, Maniwa Y. Sarcomatoid mesothelioma originating from mesothelioma in situ: are methylthioadenosine phosphorylase loss and CDKN2A homozygous deletion

poor prognostic factors for preinvasive mesothelioma? Virchows Arch.

2022;481:307–12. https://​doi.​org/​10.​1007/​s00428-​022-​03281-z.

6. Hjerpe A, Ascoli V, Bedrossian CWM, Boon ME, Creaney J, Davidson B,

et al. Guidelines for the cytopathologic diagnosis of epithelioid and

mixed-type malignant mesothelioma. Complementary statement from

the International Mesothelioma Interest Group, also endorsed by the

International Academy of Cytology and the Papanicolaou Society of

Cytopathology. Acta Cytol. 2015;59:2–16. https://​doi.​org/​10.​1159/​00037​

7697

7. Matsumoto S, Nabeshima K, Kamei T, Hiroshima K, Kawahara K, Hata

S, et al. Morphology of 9p21 homozygous deletion-positive pleural

mesothelioma cells analyzed using fluorescence in situ hybridization

and virtual microscope system in effusion cytology. Cancer Cytopathol.

2013;121:415–22. https://​doi.​org/​10.​1002/​cncy.​21269.

8. Matsumoto S, Hamasaki M, Kinoshita Y, Kamei T, Kawahara K, Nabeshima

K. Morphological difference between pleural mesothelioma cells in

effusion smears with either BAP1 loss or 9p21 homozygous deletion

Yoshida et al. Diagnostic Pathology

9. 10. 11. 12. 13. 14. 15. (2023) 18:126

Page 7 of 7

and reactive mesothelial cells without the gene alterations. Pathol Int.

2019;69:637–45. https://​doi.​org/​10.​1111/​pin.​12862.

Whitaker D, Henderson DW, Shilkin KB. The concept of mesothelioma

in situ: implications for diagnosis and histogenesis. Semin Diagn Pathol.

1992;9:151–61.

Churg A, Galateau-Salle F, Roden AC, Attanoos R, von der Thusen JH, Tsao

MS, et al. Malignant mesothelioma in situ: morphologic features and

clinical outcome. Mod Pathol. 2020;33:297–302. https://​doi.​org/​10.​1038/​

s41379-​019-​0347-0.

Churg A, Naso JR. The separation of benign and malignant mesothelial

proliferations: new markers and how to use them. Am. J. Surg. Pathol.

2020;44:e100–12). https://​doi.​org/​10.​1097/​PAS.​00000​00000​001565

Kinoshita Y, Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, et al.

A combination of MTAP and BAP1 immunohistochemistry in pleural

effusion cytology for the diagnosis of mesothelioma. Cancer Cytopathol.

2018;126:54–63. https://​doi.​org/​10.​1002/​cncy.​21928.

Hamasaki M, Matsumoto S, Abe S, Hamatake D, Kamei T, Hiroshima

K, et al. Low homozygous/high heterozygous deletion status by p16

FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma. Lung Cancer.

2016;99:155–61. https://​doi.​org/​10.​1016/j.​lungc​an.​2016.​07.​011.

Klebe S, Nakatani Y, Dobra K, Butnor KJ, Roden AC, Nicholson AG, et al.

The concept of mesothelioma in situ, with consideration of its potential

impact on cytology diagnosis. Pathology. 2021;53:446–53. https://​doi.​

org/​10.​1016/j.​pathol.​2020.​12.​005.

Overholtzer M, Mailleux AA, Mouneimne G, Normand G, Schnitt SJ, King

RW, et al. A nonapoptotic cell death process, entosis, that occurs by cellin-cell invasion. Cell. 2007;131:966–79. https://​doi.​org/​10.​1016/j.​cell.​2007.​

10.​040.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research ? Choose BMC and benefit from:

• fast, convenient online submission

• thorough peer review by experienced researchers in your field

• rapid publication on acceptance

• support for research data, including large and complex data types

• gold Open Access which fosters wider collaboration and increased citations

• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

...

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文

一発検索!

この論文の関連論文を見る